Mithridion's Subtype Selective Muscarinic Agonist Platform |
In collaboration with Dr. Bill Messer, Mithridion's Chief Scientific Officer and Professor of Pharmacology at the University of Toledo, Mithridion has designed and developed small-molecule drugs (“muscarinic agonists”) that selectively activate the M1 sub-type of muscarinic receptors. In order to have a viable drug candidate, Mithridion’s M1 receptor has to achieve a combination of properties:
Mithridion has overcome these challenges using the knowledge accumulated in recent years, the powerful pharmacological tools available today, our proprietary laboratory animal models, a strong bioanalytical/ADME capability built around our triple-quad mass spectrometer, and a close coupling of pharmacology with medicinal chemistry. The Company is on track to deliver effective, safe, first-in-class muscarinic agonist drug candidates, designed to treat Alzheimer's disease and schizophrenia. For schizophrenia, the Company has an SBIR Phase II grant worth at least $920,000 supporting this drug lead optimization program.
Mithridion, Inc. | 505 Science Drive, Suite C | Madison, WI 53511 | (608) 443 2432 |